Immune-mediated experimental arthritis in IL-33 deficient mice

Cytokine

Volumn 69, Issue 1, 2014, Pages 68-74

  Talabot Ayer, Dominique ^a,b   Martin, Praxedis ^a,b   Seemayer, Christian Alexander ^c   Vigne, Solenne ^a,b   Lamacchia, Céline ^a,b   Finckh, Axel ^a   Saiji, Essia ^a   Gabay, Cem ^a,b   Palmer, Gaby ^a,b  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Arthritis; Cytokine; Immune response; Joint inflammation

Indexed keywords

BOVINE SERUM ALBUMIN; COLLAGEN TYPE 2; GAMMA INTERFERON; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 33; IL1RL1 PROTEIN, MOUSE; IMMUNOGLOBULIN G; INTERLEUKIN DERIVATIVE; INTERLEUKIN RECEPTOR; INTERLEUKIN-33, MOUSE;

ADAPTIVE IMMUNITY; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTHRITIS; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; EXPERIMENTAL ARTHRITIS; HUMORAL IMMUNITY; IMMUNE MEDIATED ARTHRITIS; IMMUNOPATHOGENESIS; LYMPH NODE CELL; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; ANIMAL; BIOSYNTHESIS; BLOOD; C57BL MOUSE; CELL PROLIFERATION; CHEMICALLY INDUCED; DBA MOUSE; DISEASE COURSE; DISEASE MODEL; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; PATHOLOGY;

ADAPTIVE IMMUNITY; ANIMALS; ARTHRITIS, EXPERIMENTAL; CELL PROLIFERATION; COLLAGEN TYPE II; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKINS; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT; RECEPTORS, INTERLEUKIN; T-LYMPHOCYTES;

EID: 84902175147     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.05.007     Document Type: Article

References (31)

1. Palmer G., Gabay C. Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol 2011, 7:321-329.
2. Baekkevold E.S., Roussigne M., Yamanaka T., Johansen F.E., Jahnsen F.L., Amalric F., et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol 2003, 163:69-79.
3. Carriere V., Roussel L., Ortega N., Lacorre D.-A., Americh L., Aguilar L., et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 2007, 104:282-287.
4. Roussel L., Erard M., Cayrol C., Girard J.-P. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Reports 2008, 9:1006-1012.
5. Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490.
6. Moussion C., Ortega N., Girard J.-P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'?. PLoS ONE 2008, 3:e3331.
7. Lamkanfi M., Dixit V.M. IL-33 raises alarm. Immunity 2009, 31:5-7.
8. Chang Y.J., Kim H.Y., Albacker L.A., Baumgarth N., McKenzie A.N., Smith D.E., et al. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol 2011, 12:631-638.
9. Oboki K., Ohno T., Kajiwara N., Arae K., Morita H., Ishii A., et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci USA 2010, 107:18581-18586.
10. Louten J., Rankin A.L., Li Y., Murphy E.E., Beaumont M., Moon C., et al. Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation. Int Immunol 2011, 23:307-315.
11. Bonilla W.V., Frohlich A., Senn K., Kallert S., Fernandez M., Johnson S., et al. The alarmin interleukin-33 drives protective antiviral CD8 T cell responses. Science 2012, 335:984-989.
12. Xu D., Jiang H.R., Kewin P., Li Y., Mu R., Fraser A.R., et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA 2008, 105:10913-10918.
13. Palmer G., Talabot-Ayer D., Lamacchia C., Toy D., Seemayer C.A., Viatte S., et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum 2009, 60:738-749.
14. Talabot-Ayer D., McKee T., Gindre P., Bas S., Baeten D.L., Gabay C., et al. Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine: Revue du Rhumatisme 2012, 79:32-37.
15. Matsuyama Y., Okazaki H., Tamemoto H., Kimura H., Kamata Y., Nagatani K., et al. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J Rheumatol 2010, 37:18-25.
16. Kaieda S., Shin K., Nigrovic P.A., Seki K., Lee R.T., Stevens R.L., et al. Synovial fibroblasts promote the expression and granule accumulation of tryptase via interleukin-33 and its receptor ST-2 (IL1RL1). J Biol Chem 2010, 285:21478-21486.
17. Mu R., Huang H.Q., Li Y.H., Li C., Ye H., Li Z.G. Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis. J Rheumatol 2010, 37:2006-2013.
18. Matsuyama Y., Okazaki H., Hoshino M., Onishi S., Kamata Y., Nagatani K., et al. Sustained elevation of interleukin-33 in sera and synovial fluids from patients with rheumatoid arthritis non-responsive to anti-tumor necrosis factor: possible association with persistent IL-1beta signaling and a poor clinical response. Rheumatol Int 2011.
19. Hong Y.S., Moon S.J., Joo Y.B., Jeon C.H., Cho M.L., Ju J.H., et al. Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J Korean Med Sci 2011, 26:1132-1139.
20. Xiangyang Z., Lutian Y., Lin Z., Liping X., Hui S., Jing L. Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis. Cytokine 2012, 58:6-9.
21. Leung B.P., Xu D., Culshaw S., McInnes I.B., Liew F.Y. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol 2004, 173:145-150.
22. Verri W.A., Souto F.O., Vieira S.M., Almeida S.C., Fukada S.Y., Xu D., et al. IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Ann Rheum Dis 2010, 69:1697-1703.
23. Pichery M., Mirey E., Mercier P., Lefrancais E., Dujardin A., Ortega N., et al. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues. in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J Immunol 2012, 188:3488-3495.
24. Hung L.Y., Lewkowich I.P., Dawson L.A., Downey J., Yang Y., Smith D.E., et al. IL-33 drives biphasic IL-13 production for noncanonical Type 2 immunity against hookworms. Proc Natl Acad Sci USA 2013, 110:282-287.
25. Martin P., Talabot-Ayer D., Seemayer C.A., Vigne S., Lamacchia C., Rodriguez E., et al. Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency. Arthritis Res Ther 2013, 15:R13.
26. Palmer G., Busso N., Aurrand-Lions M., Talabot-Ayer D., Chobaz-Peclat V., Zimmerli C., et al. Expression and function of junctional adhesion molecule-C in human and experimental arthritis. Arthritis Res Ther 2007, 9:R65.
27. Palmer G., Chobaz V., Talabot-Ayer D., Taylor S., So A., Gabay C., et al. Assessment of the efficacy of different statins in murine collagen-induced arthritis. Arthritis Rheum 2004, 50:4051-4059.
28. Camps M., Ruckle T., Ji H., Ardissone V., Rintelen F., Shaw J., et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 2005, 11:936-943.
29. Vigne S., Palmer G., Lamacchia C., Martin P., Talabot-Ayer D., Rodriguez E., et al. IL-36R ligands are potent regulators of dendritic and T cells. Blood 2011, 118:5813-5823.
30. Rabe-Hesketh S., Skrondal A. Higher level models and nested random effects multilevel and longitudinal modeling using stata 2005, Stata Press, Texas, p. 217-64.
31. Irmler I.M., Gajda M., Brauer R. Exacerbation of antigen-induced arthritis in IFN-gamma-deficient mice as a result of unrestricted IL-17 response. J Immunol 2007, 179:6228-6236. (Baltimore, Md: 1950).